Over the past four years, Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) successfully launched Caplyta (lumateperone) to treat schizophrenia and bipolar depression. Net product sales of Caplyta reached $462.2 million in 2023, reflecting 86% growth from 2022. Starting at zero in March 2020, Caplyta sales increased slowly in 2020-21 during the pandemic when the drug was indicated only for schizophrenia. Annual sales in 2021 approximated $20 million. The drug, however, took off when it was indicated for bipolar depression in December 2021.